NASDAQ:TLSI TriSalus Life Sciences Q3 2025 Earnings Report $4.75 +0.21 (+4.63%) Closing price 04:00 PM EasternExtended Trading$4.75 0.00 (0.00%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast TriSalus Life Sciences EPS ResultsActual EPSN/AConsensus EPS -$0.17Beat/MissN/AOne Year Ago EPSN/ATriSalus Life Sciences Revenue ResultsActual RevenueN/AExpected Revenue$11.76 millionBeat/MissN/AYoY Revenue GrowthN/ATriSalus Life Sciences Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time9:00AM ETConference Call ResourcesEarnings HistoryCompany Profile TriSalus Life Sciences Earnings HeadlinesTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Recommendation of "Buy" by BrokeragesOctober 15 at 2:47 AM | americanbankingnews.comTriSalus Life Sciences Reports Strong Growth Amid ChallengesAugust 14, 2025 | msn.com"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy… it's the starting gun for what I'm calling the "Great Crypto Revolution."October 16 at 2:00 AM | Crypto 101 Media (Ad)TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comTriSalus Life Sciences Reports Strong Q2 2025 GrowthAugust 13, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comSee More TriSalus Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TriSalus Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TriSalus Life Sciences and other key companies, straight to your email. Email Address About TriSalus Life SciencesTriSalus Life Sciences (NASDAQ:TLSI) is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs. The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents. TriSalus collaborates with academic medical centers and cancer research institutions across the United States to advance its candidates through regulatory and clinical milestones. By integrating novel delivery technologies with proven oncology drugs, TriSalus seeks to optimize therapeutic outcomes in both recurrent and metastatic disease settings. Headquartered in Houston, Texas, TriSalus operates research and development facilities in strategic North American life-science hubs. Its leadership team brings together seasoned professionals with backgrounds in pharmaceutical development, medical devices, and oncology therapeutics. As the company progresses through clinical validation, it plans to expand its technology platform into additional solid tumor indications, aiming to provide safer, more effective treatment options for cancer patients worldwide.View TriSalus Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings American Express (10/17/2025)HDFC Bank (10/17/2025)Truist Financial (10/17/2025)Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
